Work

Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases

Year: 2024

Type: article

Abstract: Idiopathic nephrotic syndrome (NS) is characterized by severe proteinuria, hypoalbuminemia, and/or edema and affects about 1 to 3 per 100,000 children and young adults.1 Corticosteroids represent the first line therapy for primary NS, leading to disease remission in 70% to 80% of cases.2 However, 70% to 80% may relapse after steroid withdrawal, and approximately 10% to 30% of patients have steroid-resistant NS. Treatment of steroid-resistant NS includes calcineurin inhibitors, mycophenolate mofetil, and anti-CD20 monoclonal antibodies (rituximab or obinutuzumab) used alone or in combination.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2024.04.006